ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

ultomiris ravulizumab rch 300 mg in 3 ml (100 mg/ml) concentrated solution for injection by intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

BESPONSA inotuzumab ozogamicin 1 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

besponsa inotuzumab ozogamicin 1 mg powder for injection vial

pfizer australia pty ltd - inotuzumab ozogamicin, quantity: 1 mg - injection, powder for - excipient ingredients: sucrose; trometamol; sodium chloride; polysorbate 80 - besponsa is indicated for the treatment of adults with relapsed or refractory cd22-positive b-cell precursor acute lymphoblastic leukaemia (all).

MYLOTARG gemtuzumab ozogamicin 5 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

mylotarg gemtuzumab ozogamicin 5 mg powder for injection vial

pfizer australia pty ltd - gemtuzumab ozogamicin, quantity: 5 mg - injection, powder for - excipient ingredients: sucrose; dextran 40; sodium chloride; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - mylotarg is indicated for combination therapy with standard anthracycline and cytarabine (arac) for the treatment of patients age 15 years and above with previously untreated, de novo cd33-positive acute myeloid leukaemia (aml), except acute promyelocytic leukaemia (apl) (see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

EMGALITY galcanezumab 120mg/mL prefilled pen Australia - English - Department of Health (Therapeutic Goods Administration)

emgality galcanezumab 120mg/ml prefilled pen

eli lilly australia pty ltd - galcanezumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; water for injections; histidine; sodium chloride; polysorbate 80 - emgality is indicated for the prophylaxis of migraine in adults.

EMGALITY galcanezumab 120mg/mL prefilled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

emgality galcanezumab 120mg/ml prefilled syringe

eli lilly australia pty ltd - galcanezumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine; water for injections; polysorbate 80; sodium chloride; histidine hydrochloride monohydrate - emgality is indicated for the prophylaxis of migraine in adults.

AJOVY fremanezumab 225 mg/1.5 mL solution for injection in a pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

ajovy fremanezumab 225 mg/1.5 ml solution for injection in a pre-filled syringe

teva pharma australia pty ltd - fremanezumab, quantity: 225 mg - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; histidine; polysorbate 80; disodium edetate; sucrose; water for injections - ajovy is indicated for the preventive treatment of migraine in adults.

AJOVY fremanezumab 225 mg/1.5 mL solution for injection in an autoinjector Australia - English - Department of Health (Therapeutic Goods Administration)

ajovy fremanezumab 225 mg/1.5 ml solution for injection in an autoinjector

teva pharma australia pty ltd - fremanezumab, quantity: 225 mg - injection, solution - excipient ingredients: histidine; disodium edetate; histidine hydrochloride monohydrate; polysorbate 80; sucrose; water for injections - ajovy is indicated for the preventive treatment of migraine in adults.

BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

beovu brolucizumab (rbe) 120 mg/ml solution for injection in pre-filled syringe

novartis pharmaceuticals australia pty ltd - brolucizumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: water for injections; polysorbate 80; sucrose; sodium citrate - beovu is indicated for the treatment of: ? neovascular (wet) age-related macular degeneration (amd). ? diabetic macular oedema (dme).

BIMZELX bimekizumab 160 mg/1 mL solution for injection auto-injector Australia - English - Department of Health (Therapeutic Goods Administration)

bimzelx bimekizumab 160 mg/1 ml solution for injection auto-injector

ucb australia pty ltd t/a ucb pharma division of ucb australia - bimekizumab, quantity: 160 mg/ml - injection - excipient ingredients: polysorbate 80; water for injections; glacial acetic acid; glycine; sodium acetate trihydrate - bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

BIMZELX bimekizumab 160 mg/1 mL solution for injection safety syringe Australia - English - Department of Health (Therapeutic Goods Administration)

bimzelx bimekizumab 160 mg/1 ml solution for injection safety syringe

ucb australia pty ltd t/a ucb pharma division of ucb australia - bimekizumab, quantity: 160 mg/ml - injection - excipient ingredients: glacial acetic acid; polysorbate 80; sodium acetate trihydrate; glycine; water for injections - bimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.